

Special Issue

Inflammatory Bowel Disease and Infection

Message from the Guest Editor

The connection between inflammatory bowel disease (IBD) and infections was established soon after the classification of both Crohn's disease (CD) and ulcerative colitis (UC). It is now clear that infections play an important role in pathogenesis, clinical course, and disease exacerbations during IBD. Moreover, the disease itself predisposes patients to various infections, and the infection risk rises even higher during therapy, as the most commonly used medications induce immunomodulation and inhibition. Hence, various drugs have been shown to expose patients to specific infectious agents (e.g., tuberculosis, herpes zoster). Furthermore, immunomodulation affects response to vaccinations, thus further increasing patients' exposure to infections. As a consequence, national and international guidelines support screening tests, pretreatment vaccinations, and prophylactic therapy for specific cases. Gathering new information on any of these subjects may lead to a better understanding of the mechanism and risk factors and may help in risk stratification and the development of new therapeutic and prophylactic approaches

Guest Editor

Dr. Adi Lahat

Department of Gastroenterology, Chaim Sheba Medical Center,
Affiliated to Tel Aviv University, Tel Aviv, Israel

Deadline for manuscript submissions

closed (27 January 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/89603

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).